Rituximab, a chimeric anti-CD20 monoclonal antibody (mAb), has been used in polyneuropathy associated with anti-MAG antibody polyneuropathy with controversial results. Herein, we report on two patients with anti-MAG antibody neuropathy and concurrent chronic lymphocytic leukemia (CLL), who dramatically responded to obinutuzumab, a novel glycoengineered humanized anti-CD20 mAb.
Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy
Chiara Briani
;Andrea Visentin;Alessandro Salvalaggio;Mario Cacciavillani;Livio Trentin
2019
Abstract
Rituximab, a chimeric anti-CD20 monoclonal antibody (mAb), has been used in polyneuropathy associated with anti-MAG antibody polyneuropathy with controversial results. Herein, we report on two patients with anti-MAG antibody neuropathy and concurrent chronic lymphocytic leukemia (CLL), who dramatically responded to obinutuzumab, a novel glycoengineered humanized anti-CD20 mAb.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Briani C.ene.13838.pdf
non disponibili
Tipologia:
Published (publisher's version)
Licenza:
Accesso privato - non pubblico
Dimensione
285.95 kB
Formato
Adobe PDF
|
285.95 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
